Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial assessing SFA-001N in patients with non-alcoholic steatohepatitis (NASH) with or without fibrosis

Next Previous
X
Search
Trial Profile

A clinical trial assessing SFA-001N in patients with non-alcoholic steatohepatitis (NASH) with or without fibrosis

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 06 Jan 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SFA 001 (Primary)
  • Indications Fibrosis; Non-alcoholic steatohepatitis
  • Focus Adverse reactions

    • Most Recent Events

    • 06 Jan 2023 New trial record
    • 04 Jan 2023 According to SFA Therapeutics media release, the company has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to investigate SFA-001; the company looks forward to initiate this study in Q1 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top